Clinical trials: Solid Tumor, completed
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
EXERCISING TOGETHER for Couples Coping With Cancer
The Exercising Together trial is a single-blind, parallel group, randomized controlled trial comparing 3 arms: Arm 1 (experimental): Exercising Together where couples perform partnered exercise in a supervised, group setting…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
- Trial name
- NCT03630354
- Testing
- Exercise Intervention (supervised), Exercise Intervention (unsupervised), Informational Intervention
- Where
- United States
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Impact of Aminoglycosides in Hypotensive Septic Oncology Patients
This study evaluates the impact of aminoglycosides in hypotensive septic oncologic patients. In the oncologic patient population, sepsis is a major health concern due to high mortality rates and healthcare costs.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Septicemia
- Trial name
- NCT05045963
- Testing
- Electronic Health Record Review
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
This is a Phase 1, open label, dose escalation study of ARQ 197 in patients with advanced/recurrent solid tumors. The purpose of this study is to determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
- Trial name
- NCT00609921
- Testing
- ARQ197
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Advanced or Metastatic Solid Tumors
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.
- Trial name
- NCT04843709
- Testing
- MRG004A
- Where
- 9 sites in United States, China
- Volunteers
- 39 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered…
- Trial name
- NCT02508532
- Testing
- Avapritinib
- Where
- 19 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Blueprint Medicines Corporation
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00138216
- Testing
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Where
- 18 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
Neoplasms
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
To identify the Maximum Tolerated Dose (MTD) of afatinib in combination with vinorelbine i.v. by assessment of Dose Limiting Toxicities (DLT); To assess safety and anti-tumour efficacy and determine pharmacokinetic…
- Trial name
- NCT01214616
- Testing
- afatinib 20mg, afatinib 40mg, vinorelbine IV 25 or 20mg/m2
- Where
- 4 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Boehringer Ingelheim
Cancer, Advanced Solid Tumor
Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors
This study will characterize the safety, tolerability, biological activity, and pharmacokinetics of LBH589 in Japanese patients with advanced solid tumors whose disease has progressed despite standard therapies, or for whom no…
- Trial name
- NCT00739414
- Testing
- LBH589
- Where
- 3 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558).
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only)
- Trial name
- NCT02335918
- Testing
- Combination of varlilumab and nivolumab
- Where
- 19 sites in United States
- Volunteers
- 175 people
- Sponsor
- Celldex Therapeutics
Advanced Solid Tumors
Study of Relatlimab in Combination With Nivolumab in Chinese Participants
The purpose of this study is to evaluate the safety and drug levels of relatlimab combined with nivolumab in Chinese participants with advanced solid tumors.
- Trial name
- RELATIVITY-111 (NCT05498480)
- Testing
- Relatlimab, Nivolumab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Bristol-Myers Squibb
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain.
- Trial name
- NCT05506982
- Testing
- Psilocybin, Psychotherapy, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Tumors
A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.
- Trial name
- NCT00373490
- Testing
- Vorinostat
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Melanoma
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors
In this phase I/II trial, immunostimulatory gene therapy (AdCD40L) will be investigated. In Part 1 patients with melanoma will receive AdCD40L as mono therapy.
- Trial name
- NCT01455259
- Testing
- AdCD40L
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Uppsala University
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies…
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma
- Trial name
- NCT01421524
- Testing
- CC-122
- Where
- 39 sites in United States, Belgium and 3 more
- Volunteers
- 271 people
- Sponsor
- Celgene
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.
- Trial name
- NCT01898130
- Testing
- bevacizumab, quality-of-life assessment
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Fallopian Tube Cancer, Ovarian Cancer
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Topotecan may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00045175
- Testing
- 7-hydroxystaurosporine, topotecan hydrochloride
- Where
- 3 sites in Canada
- Volunteers
- 33 people
- Sponsor
- University Health Network, Toronto
Advanced Solid Tumor
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
In this study, MEK162 will be administered to Japanese patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists.
- Trial name
- NCT01469130
- Testing
- MEK162
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Neoplasms
Phase I Study in Patients With Solid Tumours
This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol.
- Trial name
- NCT00496028
- Testing
- AZD0530, Carboplatin, Paclitaxel
- Where
- 7 sites in France, Netherlands and 2 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Unspecified Adult Solid Tumor, Protocol Specific
Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of sirolimus in treating patients with…
- Trial name
- NCT00368914
- Testing
- sirolimus, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.